Reuters logo
BRIEF-Daiichi Sankyo announces top-line results from phase 3 global clinical development program evaluating mirogabalin in pain syndromes
2017年6月30日 / 上午11点18分 / 4 个月前

BRIEF-Daiichi Sankyo announces top-line results from phase 3 global clinical development program evaluating mirogabalin in pain syndromes

June 30 (Reuters) - Daiichi Sankyo Co Ltd

* Daiichi Sankyo announces top-line results from phase 3 global clinical development program evaluating mirogabalin in pain syndromes

* Daiichi Sankyo Co Ltd - Preliminary and ongoing analyses indicated no unexpected safety concerns in neucourse or alday clinical trials

* Daiichi Sankyo Co Ltd - In phase 3 alday clinical trials, mirogabalin did not meet primary efficacy endpoint

* Says ‍in neucourse, mirogabalin met primary efficacy endpoint​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below